New pill aims to slow Alzheimer's before it worsens
NCT ID NCT07579884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill called RP902 in 360 people with mild cognitive impairment caused by Alzheimer's disease. Participants will take the drug or a placebo for 48 weeks to see if it slows memory decline. The trial is conducted at about 50 sites in China and may extend for up to 96 more weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP902 tablets
What this could lead to
If successful, this could point toward a treatment to slow cognitive decline in early Alzheimer's disease.
What could go wrong
This is an early Phase 2 trial, so results may not confirm efficacy. The drug could fail to show benefit or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••